drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (ADC)
drug_description
HER2-directed antibody–drug conjugate consisting of an anti-HER2 monoclonal antibody linked to the microtubule inhibitor MMAE; binds HER2 on tumor cells, is internalized, and releases MMAE to inhibit tubulin polymerization, causing mitotic arrest and apoptosis; may also induce ADCC and immunogenic cell death.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Disitamab Vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-directed antibody–drug conjugate in which an anti-HER2 monoclonal antibody delivers the microtubule inhibitor MMAE to HER2-expressing tumor cells. After binding and internalization, MMAE is released to inhibit tubulin polymerization, causing mitotic arrest and apoptosis; the antibody component may also mediate ADCC and promote immunogenic cell death.
drug_name
Disitamab vedotin (RC48)
nct_id_drug_ref
NCT05912816